Head-to-head · WeighScore
Next Vial vs Willow
The verdict
Next Vial takes it — 59.3/100 to 58.2/100, but only just.
Next Vial grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fully online GLP-1 telehealth marketplace connecting patients with licensed providers for compounded semaglutide and tirzepatide injections, including microdose options. Willow is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Next Vial | Willow |
|---|---|---|
| WeighScore | 59.3/100 | 58.2/100 |
| Grade | C | C |
| Scorecard rank | #345 | #377 |
| Semaglutide | $250/mo (compounded) | $299/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $399/mo (starting dose, compounded) |
| Coverage | 49 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #345 · C
Strengths
- LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
- No membership fees — one all-in price covering consultation, medication, and shipping
- Compounded semaglutide, tirzepatide, and microdose options available
- Free rushed shipping; serves 49 states nationwide
- Board-certified physician oversight with ongoing provider support
Where it loses points
- Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
- Compounded medications are not FDA-approved
- Labs and nutritional coaching not disclosed
- Microdose pricing not published on product page
- Alaska not listed among served states
Graded #377 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.